Equity Profile

CELC

Celcuity Inc.

Health CareBiotechnology$5.1B

Aug13Thu

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Celcuity Inc. is a biotechnology company focused on developing innovative cancer therapies....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a critical measure of a company's profitability and will indicate how well Celcuity is managing its costs and revenue.

N/A

Revenue Growth

Understanding revenue trends will provide insight into the demand for Celcuity's products and therapies.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

CELC Q2-2026 Earnings Preview

Context

Company Snapshot

Celcuity Inc. is a biotechnology company focused on developing innovative cancer therapies. With a market cap of $5 billion, it operates in the health care sector, aiming to improve treatment outcomes for patients with complex cancers.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+10.76%

Avg Stock Reaction

+1.94%

Last Quarter Recap

In Q1-2026, Celcuity reported an EPS of -$0.86, outperforming expectations by nearly 20%. The stock reacted positively, gaining over 8% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic ahead of the earnings report, especially given the company's recent performance exceeding expectations. However, uncertainty remains due to the lack of specific guidance from management.

Bull Case

If Celcuity continues its trend of beating EPS estimates, it could signal strong operational efficiency and boost investor confidence.

Bear Case

Conversely, if the company fails to provide clear guidance or shows signs of slowing growth, it could lead to a negative market reaction.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the latest update on clinical trial results?

Positive results could significantly enhance investor confidence and drive stock price, while negative results could have the opposite effect.

How is Celcuity managing its operational costs?

Cost management is crucial for improving EPS and overall financial health, especially in a competitive biotech landscape.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the impact of recent clinical trial successes on Celcuity's growth trajectory, which could lead to a significant upside surprise.

Supporting Evidence

Celcuity has consistently beaten EPS estimates in recent quarters, indicating strong operational performance.

The options market is pricing a larger move than historical averages, suggesting that traders anticipate a significant announcement.

Recent trends in the biotech sector show increased investor interest in companies with promising clinical data.

Key Risk

If clinical trial results exceed expectations, it could shift market sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the potential for growth against the risks associated with clinical trial outcomes and operational efficiency.

Bull Confirmed If

A clear update on successful clinical trials or new partnerships could confirm the bull case.

Bear Confirmed If

Any indication of delays or failures in clinical trials could confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±12.47%

Historical Avg

±4.1%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±12.5% while CELC has averaged ±4.1% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

73.5%

Calls (79K)P/C Ratio: 0.54Puts (54K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Celcuity beats expectations, history suggests the stock could rise by around 3.4%, confirming positive operational trends.

In-Line / Cautious

If results are in line but cautious commentary is provided, the stock may see a muted reaction as investors reassess future growth.

Miss

Should the company miss expectations, history suggests a potential decline of about 2.4%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on clinical trial outcomes and their implications for future revenue.
2Any commentary on cost management strategies and operational efficiency.
3Details on potential partnerships or collaborations that could enhance growth.
4Insights into market demand for Celcuity's therapies and products.
5Management's outlook on the competitive landscape and future growth opportunities.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

ePlus inc.

Company Snapshot

Celcuity Inc. is a biotechnology company focused on developing innovative cancer therapies....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a critical measure of a company's profitability and will indicate how well Celcuity is managing its costs and revenue.

N/A

Revenue Growth

Understanding revenue trends will provide insight into the demand for Celcuity's products and therapies.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

CELC Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+10.76%

Avg Stock Reaction

+1.94%

Last Quarter Recap

In Q1-2026, Celcuity reported an EPS of -$0.86, outperforming expectations by nearly 20%. The stock reacted positively, gaining over 8% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Celcuity continues its trend of beating EPS estimates, it could signal strong operational efficiency and boost investor confidence.

Bear Case

Conversely, if the company fails to provide clear guidance or shows signs of slowing growth, it could lead to a negative market reaction.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the latest update on clinical trial results?

Positive results could significantly enhance investor confidence and drive stock price, while negative results could have the opposite effect.

How is Celcuity managing its operational costs?

Cost management is crucial for improving EPS and overall financial health, especially in a competitive biotech landscape.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the impact of recent clinical trial successes on Celcuity's growth trajectory, which could lead to a significant upside surprise.

Supporting Evidence

Celcuity has consistently beaten EPS estimates in recent quarters, indicating strong operational performance.

The options market is pricing a larger move than historical averages, suggesting that traders anticipate a significant announcement.

Recent trends in the biotech sector show increased investor interest in companies with promising clinical data.

Key Risk

If clinical trial results exceed expectations, it could shift market sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the potential for growth against the risks associated with clinical trial outcomes and operational efficiency.

Bull Confirmed If

A clear update on successful clinical trials or new partnerships could confirm the bull case.

Bear Confirmed If

Any indication of delays or failures in clinical trials could confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±12.47%

Historical Avg

±4.1%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±12.5% while CELC has averaged ±4.1% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

73.5%

Calls (79K)P/C Ratio: 0.54Puts (54K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Celcuity beats expectations, history suggests the stock could rise by around 3.4%, confirming positive operational trends.

In-Line / Cautious

If results are in line but cautious commentary is provided, the stock may see a muted reaction as investors reassess future growth.

Miss

Should the company miss expectations, history suggests a potential decline of about 2.4%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on clinical trial outcomes and their implications for future revenue.
2Any commentary on cost management strategies and operational efficiency.
3Details on potential partnerships or collaborations that could enhance growth.
4Insights into market demand for Celcuity's therapies and products.
5Management's outlook on the competitive landscape and future growth opportunities.